<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00864331</url>
  </required_header>
  <id_info>
    <org_study_id>E33029</org_study_id>
    <nct_id>NCT00864331</nct_id>
  </id_info>
  <brief_title>Optimization of Treatment of Advanced Nonsmall Cell Lung Cancer Using Radiotherapy and Chemotherapy</brief_title>
  <official_title>Optimization of Treatment of Advanced Nonsmall Cell Lung Cancer Using Radiotherapy and Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>International Atomic Energy Agency</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>International Atomic Energy Agency</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary objectives of the study are:

      To assess the differences in survival of the two treatment options in both stage III (A and
      B) nonsmall cell lung cancer (NSCLC) (Study A) and Stage IIIB (wet) and stage IV NSCLC (Study
      B), respectively

      Secondary objectives are:

      To assess the differences in toxicity of two treatment options in both stage III (A and B)
      NSCLC (Study A) and Stage IIIB (wet) and stage IV NSCLC (Study B), and To assess the
      differences in Health Related Quality of Life (HRQoL) of two treatment options in both Study
      A and Study B
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To compare survival rates (median and 1-year), and toxicity of two treatment regimens in
      patients with locally advanced incurable NSCLC (study A), to compare survival rates (median
      and 1-year) of two treatment regimens in patients with locally advanced and metastatic NSCLC
      (study B)

      To compare HRQoL and cost effectiveness of two treatment regimens in patients with locally
      advanced incurable NSCLC (study A), and in patients with locally advanced and metastatic
      NSCLC (study B) and to evaluate the effect of HRQoL assessment on QoL dimensions
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Survival</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the differences in toxicity of two treatment options in both stage III (A and B) NSCLC (Study A) and Stage IIIB (wet) and stage IV NSCLC (Study B)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the differences in Health Related Quality of Life (HRQoL) of two treatment options in both Study A and Study B</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">251</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Radiotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>For patients in Group A (Stage IIIA or IIIB), EBRT 39 Gy in 13 daily fractions over, with no chemotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chemotherapy and radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>For patients in Group A (either stage IIIA or IIIB) receive a course of up to 3 cycles of chemotherapy followed by EBRT of 10 Gy in a single fraction or 16 Gy in 2 fractions 1 week apart.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>For patients in Group B (either stage IIIB (wet) or IV) receive up to 3 cycles of chemotherapy, and no radiotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Palliative radiotherapy and chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>For patients in Group B (either stage IIIB (wet) or IV) receive EBRT of 10 Gy in a single fraction or 16 Gy in two fractions 1 week apart, followed by up to 3 cycles of chemotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation</intervention_name>
    <description>39 Gy in 13 daily fractions of 3 Gy</description>
    <arm_group_label>Radiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Chemotherapy and radiotherapy</intervention_name>
    <description>Chemotherapy followed by low dose palliative radiotherapy</description>
    <arm_group_label>Chemotherapy and radiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chemotherapy</intervention_name>
    <description>Chemotherapy given alone</description>
    <arm_group_label>Chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Palliative radiotherapy and chemotherapy</intervention_name>
    <description>Low dose palliative radiotherapy followed by chemotherapy</description>
    <arm_group_label>Palliative radiotherapy and chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Study A Inclusion Criteria:

          -  Histologically or cytologically confirmed NSCLC

          -  Stage IIIA/IIIB staged with

          -  CT chest and upper abdomen

          -  Liver, renal, hematological reserve appropriate (according to &quot;standard&quot; institutional
             values)

          -  Brain CT and/or bone scan only if clinical symptoms request such investigation

          -  Performance status KPS 60-90

          -  No second cancer except skin non-melanoma

          -  No previous treatment

          -  Patient must be contactable for follow-up

          -  Patient to be able to start treatment within 2 weeks from randomization (institutional
             confirmation needed)

          -  Life expectancy &gt; 3 months

          -  Patient must be able and willing to give informed consent, and fill in questionnaires

        Study A Exclusion Criteria:

          -  Stage III B &quot;wet&quot; (existing pleural effusion , but not necessarily cytologically
             verified)

          -  RT field &gt; 200 cm2

          -  Pregnancy

        Study B Inclusion Criteria:

          -  KPS 60-90

          -  Stage IV and Stage III B (existing pleural effusions , but not necessarily
             cytologically verified)

          -  Histologically or cytologically confirmed

          -  CT staged disease (thorax and possible upper abdomen)

          -  No second cancer except skin non-melanoma

          -  Liver, renal, haematological reserve appropriate (according to &quot;standard&quot;
             institutional values)

          -  No previous treatment

          -  Patient must be contactable for follow-up

          -  Patient must be able and willing to give informed consent and fill in questionnaires

          -  Patient to be able to start treatment within 2 weeks from randomization (institutional
             confirmation needed)

          -  Life expectancy &gt; 3 months

        Study B Exclusion Criteria:

          -  Brain metastasis (brain CT and/or MRI not needed, unless symptoms exist - clinically
             indicated)

          -  RT field &gt; 200 cm2

          -  Pregnancy

          -  A-P separation too large to be adequately treated with 60-Co (?)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elena Fidarova, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>International Atomic Energy Agency</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Instituto de Radiomedicine</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Affiliated Hospital of Ning Xia Medical College, Department of Radiation Oncology</name>
      <address>
        <city>Yinchuan</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Zagreb Faculty of Medicine</name>
      <address>
        <city>Zagreb</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Misr Oncology Center (MOC)</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tata Memorial Centre (TMC) Department of Atomic Energy (DAE)</name>
      <address>
        <city>Mumbai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital Kuala Lumpur, Institute of Radiotherapy and Oncology</name>
      <address>
        <city>Kuala Lumpur</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sir Paul Boffa Hospital</name>
      <address>
        <city>Floriana</city>
        <country>Malta</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ministère de la Santé, Institut National d'Oncologie Sidi Mohamed Ben Abdellah</name>
      <address>
        <city>Rabat</city>
        <country>Morocco</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nuclear Medicine Oncology and Radiotherapy Institute</name>
      <address>
        <city>Islamabad</city>
        <country>Pakistan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Oncológico National</name>
      <address>
        <city>Panama City</city>
        <country>Panama</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Enfermadades Neoplasicas Depto. De Radioterapia</name>
      <address>
        <city>Lima</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Witwatersrand Johannesburg Hospital Dept of Radiation Oncology</name>
      <address>
        <city>Johannesburg</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de la Sante Publique, Institut National de Cancer Salah Azaiz</name>
      <address>
        <city>Tunis</city>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Chile</country>
    <country>China</country>
    <country>Croatia</country>
    <country>Egypt</country>
    <country>India</country>
    <country>Malaysia</country>
    <country>Malta</country>
    <country>Morocco</country>
    <country>Pakistan</country>
    <country>Panama</country>
    <country>Peru</country>
    <country>South Africa</country>
    <country>Tunisia</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 17, 2009</study_first_submitted>
  <study_first_submitted_qc>March 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2009</study_first_posted>
  <last_update_submitted>August 6, 2013</last_update_submitted>
  <last_update_submitted_qc>August 6, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 7, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>lung cancer</keyword>
  <keyword>nonsmall cell lung cancer</keyword>
  <keyword>radiation therapy</keyword>
  <keyword>chemotherapy</keyword>
  <keyword>Locally advanced and metastatic nonsmall cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

